Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat

David W. Nelson, James W. Sharp, Mark S. Brownfield, Helen E Raybould, Denise M. Ney

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent proglucagon-derived hormone that stimulates intestinal growth through poorly understood paracrine and/or neural pathways. The relationship between GLP-2 action and a vagal pathway is unclear. Our aims were to determine whether 1) the GLP-2 receptor (GLP-2R) is expressed on vagal afferents by localizing it to the nodose ganglia; 2) exogenous GLP-2 stimulates the vagal afferent pathway by determining immunoreactivity for c-fos protein in the nucleus of the solitary tract (NTS); and 3) functional ablation of vagal afferents attenuates GLP-2-mediated intestinal growth in rats maintained with total parenteral nutrition (TPN). A polyclonal antibody against the N terminus of the rat GLP-2R was raised and characterized. The GLP-2R was localized to vagal afferents in the nodose ganglia and confirmed in enteroendocrine cells, enteric neurons, and nerve fibers in the myenteric plexus using immunohistochemistry. Activation of the vagal afferent pathway, as indicated by c-fos protein immunoreactivity in the NTS, was determined by immunohistochemistry after ip injection of 200 μg human GLP-2. GLP-2 induced a significant 5-fold increase in the number of c-fos protein immunoreactive neurons in the NTS compared with saline. Ablation of vagal afferent function by perivagal application of capsaicin, a specific afferent neurotoxin, abolished c-fos protein immunoreactivity, suggesting that activation of the NTS due to GLP-2 is dependent on vagal afferents. Exogenous GLP-2 prevented TPN-induced mucosal atrophy, but ablation of vagal afferent function with capsaicin did not attenuate this effect. This suggests that vagal-independent pathways are responsible for GLP-2 action in the absence of luminal nutrients during TPN, possibly involving enteric neurons or endocrine cells. This study shows for the first time that the GLP-2Ris expressed by vagal afferents, and ip GLP-2 activates the vagal afferent pathway.

Original languageEnglish (US)
Pages (from-to)1954-1962
Number of pages9
JournalEndocrinology
Volume148
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

Glucagon-Like Peptide 2
Proto-Oncogene Proteins c-fos
Afferent Pathways
Total Parenteral Nutrition
Nodose Ganglion
Capsaicin
Neurons
Proglucagon
Immunohistochemistry
Glucagon-Like Peptide-2 Receptor
Enteroendocrine Cells
Gastrointestinal Hormones
Food
Neural Pathways
Myenteric Plexus
Solitary Nucleus
Endocrine Cells
Growth
Nerve Fibers
Atrophy

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. / Nelson, David W.; Sharp, James W.; Brownfield, Mark S.; Raybould, Helen E; Ney, Denise M.

In: Endocrinology, Vol. 148, No. 5, 05.2007, p. 1954-1962.

Research output: Contribution to journalArticle

Nelson, David W. ; Sharp, James W. ; Brownfield, Mark S. ; Raybould, Helen E ; Ney, Denise M. / Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. In: Endocrinology. 2007 ; Vol. 148, No. 5. pp. 1954-1962.
@article{0bb1fc5271d94384a7bc31e29cb042fa,
title = "Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat",
abstract = "Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent proglucagon-derived hormone that stimulates intestinal growth through poorly understood paracrine and/or neural pathways. The relationship between GLP-2 action and a vagal pathway is unclear. Our aims were to determine whether 1) the GLP-2 receptor (GLP-2R) is expressed on vagal afferents by localizing it to the nodose ganglia; 2) exogenous GLP-2 stimulates the vagal afferent pathway by determining immunoreactivity for c-fos protein in the nucleus of the solitary tract (NTS); and 3) functional ablation of vagal afferents attenuates GLP-2-mediated intestinal growth in rats maintained with total parenteral nutrition (TPN). A polyclonal antibody against the N terminus of the rat GLP-2R was raised and characterized. The GLP-2R was localized to vagal afferents in the nodose ganglia and confirmed in enteroendocrine cells, enteric neurons, and nerve fibers in the myenteric plexus using immunohistochemistry. Activation of the vagal afferent pathway, as indicated by c-fos protein immunoreactivity in the NTS, was determined by immunohistochemistry after ip injection of 200 μg human GLP-2. GLP-2 induced a significant 5-fold increase in the number of c-fos protein immunoreactive neurons in the NTS compared with saline. Ablation of vagal afferent function by perivagal application of capsaicin, a specific afferent neurotoxin, abolished c-fos protein immunoreactivity, suggesting that activation of the NTS due to GLP-2 is dependent on vagal afferents. Exogenous GLP-2 prevented TPN-induced mucosal atrophy, but ablation of vagal afferent function with capsaicin did not attenuate this effect. This suggests that vagal-independent pathways are responsible for GLP-2 action in the absence of luminal nutrients during TPN, possibly involving enteric neurons or endocrine cells. This study shows for the first time that the GLP-2Ris expressed by vagal afferents, and ip GLP-2 activates the vagal afferent pathway.",
author = "Nelson, {David W.} and Sharp, {James W.} and Brownfield, {Mark S.} and Raybould, {Helen E} and Ney, {Denise M.}",
year = "2007",
month = "5",
doi = "10.1210/en.2006-1232",
language = "English (US)",
volume = "148",
pages = "1954--1962",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat

AU - Nelson, David W.

AU - Sharp, James W.

AU - Brownfield, Mark S.

AU - Raybould, Helen E

AU - Ney, Denise M.

PY - 2007/5

Y1 - 2007/5

N2 - Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent proglucagon-derived hormone that stimulates intestinal growth through poorly understood paracrine and/or neural pathways. The relationship between GLP-2 action and a vagal pathway is unclear. Our aims were to determine whether 1) the GLP-2 receptor (GLP-2R) is expressed on vagal afferents by localizing it to the nodose ganglia; 2) exogenous GLP-2 stimulates the vagal afferent pathway by determining immunoreactivity for c-fos protein in the nucleus of the solitary tract (NTS); and 3) functional ablation of vagal afferents attenuates GLP-2-mediated intestinal growth in rats maintained with total parenteral nutrition (TPN). A polyclonal antibody against the N terminus of the rat GLP-2R was raised and characterized. The GLP-2R was localized to vagal afferents in the nodose ganglia and confirmed in enteroendocrine cells, enteric neurons, and nerve fibers in the myenteric plexus using immunohistochemistry. Activation of the vagal afferent pathway, as indicated by c-fos protein immunoreactivity in the NTS, was determined by immunohistochemistry after ip injection of 200 μg human GLP-2. GLP-2 induced a significant 5-fold increase in the number of c-fos protein immunoreactive neurons in the NTS compared with saline. Ablation of vagal afferent function by perivagal application of capsaicin, a specific afferent neurotoxin, abolished c-fos protein immunoreactivity, suggesting that activation of the NTS due to GLP-2 is dependent on vagal afferents. Exogenous GLP-2 prevented TPN-induced mucosal atrophy, but ablation of vagal afferent function with capsaicin did not attenuate this effect. This suggests that vagal-independent pathways are responsible for GLP-2 action in the absence of luminal nutrients during TPN, possibly involving enteric neurons or endocrine cells. This study shows for the first time that the GLP-2Ris expressed by vagal afferents, and ip GLP-2 activates the vagal afferent pathway.

AB - Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent proglucagon-derived hormone that stimulates intestinal growth through poorly understood paracrine and/or neural pathways. The relationship between GLP-2 action and a vagal pathway is unclear. Our aims were to determine whether 1) the GLP-2 receptor (GLP-2R) is expressed on vagal afferents by localizing it to the nodose ganglia; 2) exogenous GLP-2 stimulates the vagal afferent pathway by determining immunoreactivity for c-fos protein in the nucleus of the solitary tract (NTS); and 3) functional ablation of vagal afferents attenuates GLP-2-mediated intestinal growth in rats maintained with total parenteral nutrition (TPN). A polyclonal antibody against the N terminus of the rat GLP-2R was raised and characterized. The GLP-2R was localized to vagal afferents in the nodose ganglia and confirmed in enteroendocrine cells, enteric neurons, and nerve fibers in the myenteric plexus using immunohistochemistry. Activation of the vagal afferent pathway, as indicated by c-fos protein immunoreactivity in the NTS, was determined by immunohistochemistry after ip injection of 200 μg human GLP-2. GLP-2 induced a significant 5-fold increase in the number of c-fos protein immunoreactive neurons in the NTS compared with saline. Ablation of vagal afferent function by perivagal application of capsaicin, a specific afferent neurotoxin, abolished c-fos protein immunoreactivity, suggesting that activation of the NTS due to GLP-2 is dependent on vagal afferents. Exogenous GLP-2 prevented TPN-induced mucosal atrophy, but ablation of vagal afferent function with capsaicin did not attenuate this effect. This suggests that vagal-independent pathways are responsible for GLP-2 action in the absence of luminal nutrients during TPN, possibly involving enteric neurons or endocrine cells. This study shows for the first time that the GLP-2Ris expressed by vagal afferents, and ip GLP-2 activates the vagal afferent pathway.

UR - http://www.scopus.com/inward/record.url?scp=34249806738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249806738&partnerID=8YFLogxK

U2 - 10.1210/en.2006-1232

DO - 10.1210/en.2006-1232

M3 - Article

C2 - 17234710

AN - SCOPUS:34249806738

VL - 148

SP - 1954

EP - 1962

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 5

ER -